A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
Conditions
Sickle Cell Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The Hospital for Sick Children, Toronto, Ontario, Canada
APHP - Centre de Référence des Syndromes, Paris, France
Hospices Civils de Lyon-Hopital Lyon Sud, Pierre-Bénite, France
Centre Hospitalier Universitaire de Rouen-Hopital Charles Nicolle, Roeun, France
KEMRI-Walter-Reed Kericho, Kericho, Kenya
Kombewa Clinical Research Centre, Kisumu, Kenya
Ahero Clinical Trials Unit, Kisumu, Kenya
Kenya Medical Research Institute-Centre for Respiratory Disease Research, Siaya Clinical Research Annexe, Siaya, Kenya
American University of Beirut Medical center, Beirut, Lebanon
Hospital Nini, Tripoli, Lebanon
University of Nigeria Teaching Hospital (UNTH), Ituku-Ozalla, Enugu State, Nigeria
Lagos University Teaching Hospital, Lagos, Lagos, Nigeria
Aminu Kano Teaching Hospital (AKTH), Tarauni, Nigeria
Hacettepe University pediatric hematology, Ankara, Turkey (Türkiye)
Acıbadem Adana Hastanesi, Seyhan, Turkey (Türkiye)
Guys and St Thomas NHS Foundation Trust / Evelina Childrens Hospital, London, United Kingdom
King's College Hospital - Alex Mowat Research Hub, London, United Kingdom
Manchester Royal Infirmary_1, Manchester, United Kingdom
Study leads
Clinical Transparency (dept. 2834)
Study Director
Novo Nordisk A/S